StreetInsider.com News Articles

Form 8-K Tivic Health Systems, For: Mar 11

Wed, 11 Mar 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260311/26147177.html

Form 8-K Tivic Health Systems, For: Mar 11

Wed, 11 Mar 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260311/26147177.html

Form 8-K Tivic Health Systems, For: Mar 02

Wed, 04 Mar 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260304/26107740.html

Form 8-K Tivic Health Systems, For: Mar 02

Wed, 04 Mar 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260304/26107740.html

Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma

Wed, 04 Mar 2026 08:30:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / March 4, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC) ("Tivic" or the "Company"), a late-stage immunotherapeutics company, today announced that its Board of Directors has appointed Michael K. Handley as Chief Executive Officer of Tivic, effective immediately. Mr. Handley succeeds Jennifer Ernst, who has served as CEO since its founding in 2016 and is stepping down from the CEO role as the Company enters its next chapter. Ms. Ernst will continue to support the Company through this strategic transition.

The appointment of Mr. Handley marks a

Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma

Wed, 04 Mar 2026 08:30:00 -0400

The appointment of Mr. Handley marks a

Form SCHEDULE 13G Tivic Health Systems, Filed by: 3i, LP

Fri, 27 Feb 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260227/26081579.html

Form SCHEDULE 13G Tivic Health Systems, Filed by: 3i, LP

Fri, 27 Feb 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260227/26081579.html

Form 8-K/A Tivic Health Systems, For: Dec 09

Mon, 23 Feb 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260223/26044609.html

Form 8-K/A Tivic Health Systems, For: Dec 09

Mon, 23 Feb 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260223/26044609.html

Form 4 Tivic Health Systems, For: Feb 18 Filed by: Handley Michael K

Fri, 20 Feb 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260220/26036346.html

Form 4 Tivic Health Systems, For: Feb 18 Filed by: Handley Michael K

Fri, 20 Feb 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260220/26036346.html

Tivic schedules follow-up meeting with BARDA on radiation drug

Wed, 18 Feb 2026 09:29:49 -0400

Tivic Health Systems (NASDAQ: TIVC) announced a second meeting with the Biomedical Advanced Research and Development Authority has been scheduled for March 10, 2026, to discuss clinical data and potential funding for Entolimod for Acute Radiation Syndrome.

The company presented clinical data for its Toll-like Receptor 5 agonist Entolimod at an initial TechWatch meeting with BARDA on January 26, 2026. Following the presentation, government attendees recommended scheduling a follow-up meeting, according to the company's statement.

"We see this invitation by the U.S. government to return for further discussions on the differentiated properties of Entolimod as a promising sign," said Chief Executive Officer

Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10

Wed, 18 Feb 2026 09:15:00 -0400

Initial presentation on January 26, 2026 showcased Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure.

FREMONT, CA / ACCESS Newswire / February 18, 2026 / Tivic (Nasdaq:TIVC), a late-stage immuno-therapeutics company, today announced that a second, follow-up meeting with the Biomedical Advanced Research and Development Authority (BARDA) has been scheduled for March 10, 2026, to continue discussions focused on clinical data and the potential for funding and, ultimately, stockpiling Entolimod™ for Acute Radiation Syndrome (ARS).

On January 26, 2026, Tivic attended an initial TechWatch meeting with BARDA

Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10

Wed, 18 Feb 2026 09:15:00 -0400

Initial presentation on January 26, 2026 showcased Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure.

On January 26, 2026, Tivic attended an initial TechWatch meeting with BARDA

Form DEFA14A Tivic Health Systems,

Mon, 09 Feb 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260209/25968858.html

Form DEFA14A Tivic Health Systems,

Mon, 09 Feb 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260209/25968858.html

Form 8-K Tivic Health Systems, For: Feb 06

Mon, 09 Feb 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260209/25968853.html

Form 8-K Tivic Health Systems, For: Feb 06

Mon, 09 Feb 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260209/25968853.html

Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting

Wed, 28 Jan 2026 08:30:00 -0400

January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure
BARDA has requested a follow-up meeting to continue the discussion on the potential utility of Entolimod as a drug for the Strategic National Stockpile
Showcased clinical results, regulatory progression, and manufacturing readiness accelerated by newly formed subsidiary Velocity Bioworks^™

FREMONT, CA / ACCESS Newswire / January 28, 2026 / Tivic Health^® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that it delivered an invited presentation at a TechWatch meeting with the Biomedical

Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting

Wed, 28 Jan 2026 08:30:00 -0400

January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure
BARDA has requested a follow-up meeting to continue the discussion on the potential utility of Entolimod as a drug for the Strategic National Stockpile
Showcased clinical results, regulatory progression, and manufacturing readiness accelerated by newly formed subsidiary Velocity Bioworks^™

Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

Mon, 26 Jan 2026 10:10:00 -0400

CEO Presentation to Include Updates and Further Information on the Following Topics:

Entolimod Cell Line Verification Success;
200x Manufacturing Scale-Up with Reproducible Quality;
BARDA TechWatch Engagement;
Creation of Velocity Bioworks, An Integrated CDMO To Accelerate Commercial Readiness

FREMONT, CA / ACCESS Newswire / January 26, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that the company's CEO will present at the 3^rd Annual DealFlow Discovery Conference, set to take place on January 28-29, 2026 in Atlantic City, New Jersey.

Event Details

3rd Annual DealFlow Discovery Conference
The Borgata Hotel, Casino

Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

Mon, 26 Jan 2026 10:10:00 -0400

CEO Presentation to Include Updates and Further Information on the Following Topics:
Entolimod Cell Line Verification Success;
200x Manufacturing Scale-Up with Reproducible Quality;
BARDA TechWatch Engagement;
Creation of Velocity Bioworks, An Integrated CDMO To Accelerate Commercial Readiness
FREMONT, CA / ACCESS Newswire / January 26, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that the company's CEO will present at the 3^rd Annual DealFlow Discovery Conference, set to take place on January 28-29, 2026 in Atlantic City, New Jersey.
Event Details
3rd Annual DealFlow Discovery Conference
The Borgata Hotel, Casino

DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event

Fri, 23 Jan 2026 14:50:00 -0400

ATLANTIC CITY, NJ / ACCESS Newswire / January 23, 2026 / DealFlow Events today announced the growing list of companies scheduled to present and participate in one-on-one meetings with investors and analysts at the DealFlow Discovery Conference, taking place January 28-29, 2026, at the Borgata Hotel Casino & Spa in Atlantic City.
More than 100 public and private companies are expected to participate in the conference, which brings together investors, analysts, growth company executives, and capital markets professionals for two days of company presentations, structured networking, and pre-scheduled 1:1 meetings.
Below is the current

DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event

Fri, 23 Jan 2026 14:50:00 -0400

ATLANTIC CITY, NJ / ACCESS Newswire / January 23, 2026 / DealFlow Events today announced the growing list of companies scheduled to present and participate in one-on-one meetings with investors and analysts at the DealFlow Discovery Conference, taking place January 28-29, 2026, at the Borgata Hotel Casino & Spa in Atlantic City.
More than 100 public and private companies are expected to participate in the conference, which brings together investors, analysts, growth company executives, and capital markets professionals for two days of company presentations, structured networking, and pre-scheduled 1:1 meetings.
Below is the current